Introduction
- What have recent studies shown regarding residual CV risk in patients on statins?
- What new agents are available to address residual risk?
- What are the mechanisms of action of these therapeutics, and what patient populations do they benefit?
- What are current AACE recommendations for the use of novel new therapeutic agents for ASCVD?